NDA 050805 · Galderma Labs Lp
Oracea
Doxycycline · Oral · Tetracycline-class Drug
Last checked: Nov 19, 2026Latest source record: Apr 2, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
May 26, 2006
Approved uses
1
Original approval plus efficacy supplements
Registered trials
428
84 Phase 3, 42 recruiting
FAERS reports
52,695
40,506 serious, 4,857 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 16, 2025.
ORACEA is a tetracycline-class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ( 1. 1) Limitations of Use This formulation of doxycycline has not been evaluated in the treatment or prevention of infections. Do not use ORACEA for treating bacterial infections, providing antibacterial prophylaxis, or reducing the numbers or eliminating microorganisms associated with any bacterial disease. ( 1.2 ) ORACEA has not been evaluated for the treatment of the erythematous, telangiectatic, or ocular components of rosacea. ( 1.2 ) 1.1 Indication ORACEA is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. No meaningful effect was demonstrated for generalized erythema (redness) of rosacea. 1.2 Limitations of Use This formulation of doxycycline has not been evaluated in the treatment or prevention of infections. Do not use ORACEA for treating bacterial infections, providing antibacterial prophylaxis, or reducing the numbers or eliminating microorganisms associated with any bacterial disease. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, ORACEA should be used only as indicated. ORACEA has not been evaluated for the treatment of the erythematous, telangiectatic, or ocular components of rosacea.
Mechanism: The mechanism of action of ORACEA in the treatment of inflammatory lesions of rosacea is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ORACEA · DOXYCYCLINE 40MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Doxycycline" as an intervention, any sponsor and status, largest first.
- Antibiotic Prophylaxis in High-Risk Arthroplasty PatientsPivotal-lookingEnrolling by invitation
Mayo ClinicAcademic, hospital or other
NCT04297592 · 4,618 participants (planned) · Start Jun 11, 2020 · Primary completion Jan 2027
Drug: Cephalexin; Doxycycline and 1 more · For: Infections Joint Prosthetic; Overweight or Obesity; MSSA Colonization and 6 more
Sites: Iowa City, Iowa; Rochester, Minnesota
- Helicobacter Pylori Eradication and Follow-upStatus unknown
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05061732 · 4,447 participants (planned) · Start Sep 30, 2021 · Primary completion Jun 30, 2026
Drug: Rabeprazole; Bismuth potassium citrate and 7 more · For: Helicobacter Pylori Infection
Sites: Shanghai, China
- Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSMPivotal-lookingActive, not recruiting
University of WashingtonAcademic, hospital or other
NCT06468462 · 2,900 participants (planned) · Start Oct 29, 2025 · Primary completion Oct 31, 2028
Drug: WHO-recommended periodic presumptive treatment; Doxycycline post-exposure prophylaxis · For: Gonorrhea Male; Chlamydia (Male); Syphilis Male
Sites: Kisumu, Kenya; Mombasa, Kenya; Nairobi, Kenya
- To Compare the Strategies of Universal Antibiotic Prophylaxis Versus Screen-and-treat in Reducing Infective Complications and Re-infection in Women Who Undergo Termination of PregnancyPivotal-lookingCompleted
The University of Hong KongAcademic, hospital or other
NCT01842100 · 2,193 participants · Start Sep 1999 · Primary completion Feb 2006
Drug: Universal antibiotic prophylaxis · For: Induced Abortion; Postaboral Pelvic Inflammatory Disease; Sexually Transmitted Infections
Sites: Hong Kong, China
- The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolPivotal-lookingCompleted
The Camelot FoundationAcademic, hospital or other
NCT04349410 · 1,800 participants · Start Apr 11, 2020 · Primary completion Sep 14, 2020
Drug: Hydroxychloroquine, Azithromycin; Hydroxychloroquine, Doxycycline and 9 more · For: CoVid 19 Positive
Sites: Los Angeles, California
- AUTOP 2: Screen-and-treat Strategy for Vaginal Flora Abnormalities by Molecular Biology in Pregnant Women at High Risk of Preterm BirthPivotal-lookingNot yet recruiting
Assistance Publique Hopitaux De MarseilleAcademic, hospital or other
NCT06349122 · 1,794 participants (planned) · Start Oct 2026 · Primary completion Jun 2029
Drug: Azithromycin; Ceftriaxone and 3 more · For: Bacterial Vaginosis; Vaginal Dysbiosis; Premature Delivery
- Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic FilariasisCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00340691 · 1,500 participants · Start Dec 6, 2004 · Primary completion Oct 4, 2007
Drug: Doxycycline · For: Mansonella Perstans Infection; Mp Microfilaremia
Sites: Bethesda, Maryland
Galderma R&DIndustry
NCT00892281 · 1,421 participants · Start Apr 2009 · Primary completion Oct 2009
Drug: doxycycline (Oracea®) 40 mg modified release as monotherapy; doxycycline (Oracea®) 40 mg modified release as add-on therapy · For: Rosacea
Sites: Lexington, Kentucky
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4,245
- off label use3,726
- nausea3,620
- fatigue3,273
- dyspnoea3,083
- rash3,043
- diarrhoea2,980
- headache2,842
- pain2,833
- vomiting2,765
- malaise2,319
- condition aggravated2,182
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 221 |
| 2005 | 315 |
| 2006 | 322 |
| 2007 | 353 |
| 2008 | 425 |
| 2009 | 693 |
| 2010 | 943 |
| 2011 | 1,157 |
| 2012 | 1,296 |
| 2013 | 1,411 |
| 2014 | 1,669 |
| 2015 | 2,008 |
| 2016 | 2,598 |
| 2017 | 2,631 |
| 2018 | 3,286 |
| 2019 | 4,166 |
| 2020 | 3,994 |
| 2021 | 3,551 |
| 2022 | 3,933 |
| 2023 | 4,700 |
| 2024 | 4,938 |
| 2025 | 4,762 |
| 2026 | 3,323 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Oracea (Doxycycline Monohydrate)
2024 spending
$3.2M
Beneficiaries
750
2,605 claims
Per beneficiary
$4,325
$28.58 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,949,239 |
| 2021 | $3,585,098 |
| 2022 | $3,437,037 |
| 2023 | $3,911,292 |
| 2024 | $3,243,701 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections.
Luetkemeyer AF, Donnell D, Dombrowski JC, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Efficacy of Doxycycline for Mild-to-Moderate Community-Acquired Pneumonia in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Choi SH, Cesar A, Snow TAC, et al. · Clin Infect Dis 2023 · Meta-Analysis, Systematic Review
- Doxycycline prophylaxis for the prevention of sexually transmitted infections: A systematic review and meta-analysis of randomized controlled trials.
Szondy I, Meznerics FA, Lrincz K, et al. · Int J Infect Dis 2024 · Systematic Review, Meta-Analysis
- Intravenous Doxycycline, Azithromycin, or Both for Severe Scrub Typhus.
Varghese GM, Dayanand D, Gunasekaran K, et al. · N Engl J Med 2023 · Comparative Study, Multicenter Study
- Efficacy of Doxycycline as Preexposure and/or Postexposure Prophylaxis to Prevent Sexually Transmitted Diseases: A Systematic Review and Meta-Analysis.
Boschiero MN, Sansone NMS, Matos LR, et al. · Sex Transm Dis 2025 · Systematic Review, Meta-Analysis
- Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in Women.
Stewart J, Oware K, Donnell D, et al. · N Engl J Med 2023 · Comparative Study, Randomized Controlled Trial
Sponsor: Galderma Labs Lp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.